跳到正文
原文
ScienceDaily Health & Medicine·· 9 小时前精选AI 评分75

实验性减肥药显著减轻膝关节疼痛

Powerful new weight-loss drug helps patients cut knee pain in half

AI 导读

两项III期临床试验显示,实验性减肥药retatrutide可使患者减轻约25%体重,并显著减轻膝关节疼痛。研究还发现该药能降低血压、改善全身炎症。尽管疗效显著,但其对关节炎进展的影响尚待验证。

推荐理由

研究显示实验性减肥药可显著减轻膝关节疼痛,但其对关节炎进展的影响仍需进一步研究。

正文

For people living with painful knee osteoarthritis (OA), even simple activities like walking, climbing stairs, or getting out of a chair can become a struggle. Excess body weight can make these challenges even worse. Now, two major clinical trials suggest that a powerful experimental weight-loss drug could provide substantial relief.

The two phase 3 trials, led by Northwestern University, included more than 1,000 participants in total. People receiving the highest dose of retatrutide, an experimental injectable weight-loss medication, lost an average of about 25% of their body weight. When researchers combined the findings from both trials, they found that approximately two-thirds of participants treated with retatrutide reported a reduction in knee pain of at least 50%. By comparison, only 38% of those given a placebo experienced that level of relief.

The benefits extended beyond weight loss and improved knee pain. Participants also showed reductions in blood pressure, blood lipid levels, and inflammation throughout the body.

Findings from both studies were published on Nov. 8 in the New England Journal of Medicine.

"The findings are really saying for people who are overweight and have OA, if you lose a significant amount of weight with this treatment, there is a good chance that you're going to get a meaningful reduction in your knee pain," said corresponding author Dr. Thomas Schnitzer, professor of physical medicine and rehabilitation, anesthesiology and medicine (rheumatology) at Northwestern University Feinberg School of Medicine.

"A major factor is that you're loading your knees less and therefore, there's less pain and it allows you to increase your function."

Philip Conaghan, a study co-author and professor of musculoskeletal medicine at the University of Leeds in the United Kingdom, presented results from one of the trials, TRIUMPH-4, on Nov. 8 at the American College of Rheumatology annual meeting in Orlando, Florida. Findings from the second trial, TRIUMPH-1-OA, were scheduled for presentation during a separate poster session that same day.

A Potential New Treatment for Millions With Knee Osteoarthritis

Painful knee osteoarthritis affects approximately 5% of Americans (15 million people). Available treatments range from physical therapy and medications applied to the skin to oral anti-inflammatory drugs such as ibuprofen and Voltaren. Other options include opioids and corticosteroid injections, although the relief provided by steroid injections generally lasts only a short time.

Weight loss is another established way to ease symptoms. Previous studies have shown that losing 5% to 10% of body weight through changes in diet and exercise can improve knee osteoarthritis pain. However, Schnitzer explained that losing more than 10% through these approaches alone is often challenging. For people already struggling with painful knees, exercising enough to achieve substantial weight loss can be especially difficult.

Retatrutide could offer another approach. Developed by Eli Lilly, the experimental medication is administered as a once-weekly injection and works differently from existing GLP-1 medications such as semaglutide and tirzepatide.

While those drugs act on one or two hormone receptors and typically produce weight reductions of 10% to 20%, retatrutide activates receptors associated with three different naturally occurring hormones. In the clinical trials, participants lost approximately 20% to 25% of their body weight, depending on the dose. Eli Lilly scientists also contributed to the research as study co-authors.

"Participants had remarkable responses," Schnitzer said. "Many of the people in this study lost considerable amounts of weight, with a few losing up to a hundred pounds or more."

Why Diet and Exercise Still Matter

Despite the encouraging findings, Schnitzer emphasized that lifestyle changes should remain the starting point for people who are overweight and have painful knee osteoarthritis.

Improving eating habits, increasing physical activity, and making other sustainable lifestyle adjustments can help reduce symptoms without the expense of newer weight-loss medications. These strategies also avoid side effects associated with GLP-1 drugs, including gastrointestinal problems and muscle loss.

Maintaining muscle strength is particularly important for people with knee osteoarthritis because the muscles surrounding the joint help support and stabilize it. Losing too much muscle could therefore create additional challenges for patients who already have difficulty moving comfortably.

For individuals who cannot achieve sufficient weight loss through lifestyle changes and continue to experience significant knee pain, Schnitzer believes retatrutide could become a valuable option if it receives approval from the U.S. Food and Drug Administration.

Could the Drug Also Slow Knee Arthritis Progression?

Although the trials demonstrated substantial improvements in weight and pain, several important questions remain unanswered.

One of the biggest is whether retatrutide does more than relieve symptoms. Researchers still do not know if the drug can slow the underlying progression of knee osteoarthritis enough to reduce the likelihood that patients will eventually need knee replacement surgery. People who already required a knee replacement were excluded from the trials.

"That would be the goal here to say you can reduce people's pain, and you can stop the progression of their osteoarthritis," Schnitzer said.

Another unanswered question is whether retatrutide might benefit people with painful knee osteoarthritis who are not overweight. Because the trials did not include these patients, further studies will be needed to determine whether they could experience similar improvements.

Researchers are also interested in understanding how much of the pain relief comes directly from weight loss and how much might be related to the drug's effects on inflammation.

"These drugs are believed to have significant anti-inflammatory activity, but the mechanism is not entirely known," Schnitzer said. "Whether cutting down inflammation in the joint is also important in addition to reducing load needs more research, so this is still a first step, in my view. I've been working in the OA field for a long time, and I think this opens up opportunities to do a lot more studies to understand the condition better."

How Researchers Measured Knee Pain Relief

To evaluate changes in symptoms, the research teams used the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain index, a standardized tool for assessing osteoarthritis pain.

During study visits, participants rated their pain on a scale from 0 to 10. They also used a mobile app to record their pain levels each day, allowing researchers to track how symptoms changed throughout treatment.

The study is titled, "Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity."

来源:ScienceDaily Health & Medicine · sciencedaily.com